|
Haas et al. (2020) [14]
|
None
|
Yes
|
Morning of the trigger day
|
2016–2018
|
Age 18–41 y; BMI 18–35 kg/m2; AMH > 1 ng/ml; AFC 6–20; FSH < 20 IU/l; first three IVF cycle
|
E2 levels > 15,000 pmol/l; moderate–severe endometriosis
|
146
|
hCG 10,000 IU and GnRH agonist 0.5 mg
|
hCG 10,000 IU and placebo
|
|
Mahajan et al. (2016) [21]
|
None
|
Yes
|
NR
|
NR
|
Aged 24–43; AMH < 4 ng/ml; AFCs/ovary < 12
|
None
|
76
|
hCG 5000 IU and GnRH agonist 1 mg
|
hCG 10,000 IU
|
|
Ali et al. (2020) [13]
|
None
|
Yes
|
NR
|
2016–2018
|
First ICSI cycle; aged less than 40 y; BMI 18–30 kg/m2; AMH > 1 ng/ml; normal, mild or moderate male factor infertility
|
Azoospermic males
|
160
|
250 IU of recombinant HCG and GnRH agonist 1 mg
|
250 IU of recombinant HCG
|
|
Schachter et al. (2008) [24]
|
NR
|
Yes
|
Onset of intervention
|
NR
|
Failed at least one IVF-ET cycle on GnRH agonist long protocol; hysterosalpingogram or hysteroscopy history; BMI 18–30 kg/m2;
|
Lack of oocytes aspirated in previous cycles;
|
211
|
hCG 5000 IU and GnRH agonist 0.2 mg
|
hCG 5000 IU
|
|
Haas et al. (2019) [19]
|
None
|
Yes
|
NR
|
2015–2017
|
Poor responders defined with the Bologna criteria.
|
None
|
23
|
hCG 6500 IU and GnRH agonist (dose not reported)
|
hCG 6.500 IU
|
|
Eftekhar et al. (2017) [20]
|
None
|
Yes
|
Leading follicles reached 17 mm in diameter
|
2014–2015
|
Aged less than 42 y; BMI 18–30 kg/m2; moderate ovarian response
|
Endocrine disorders; PCOS; UA; RIF; azoospermia; day-3 FSH ≥ 10 IU/L or AMH ≤1.0 ng/mL
|
192
|
hCG 6500 IU and GnRH agonist 0.2 mg
|
hCG 6.500 IU
|
|
Kim et al. (2014) [22]
|
NR
|
Yes
|
NR
|
NR
|
Women with regular ovulatory cycles
|
PCOS, metabolic disorders
|
120
|
250 μg rhCG and GnRH agonist 0.1 mg
|
250 μg rhCG and placebo
|
|
Decleer et al. (2014) [23]
|
NR
|
Yes
|
NR
|
2011–2013
|
Tubal or male infertility, BMI < 32, age ≤ 38 y, frst, second and third IVF cycle.
|
Azospermia, UA, PCOS, endocrine disorders, endometriosis
|
120
|
hCG 5000 IU and GnRH agonist 0.2 mg
|
hCG 5000 IU
|
